Multi-institutional phase II trial of S-1 in patients with oral squamous cell carcinoma

Anti-Cancer Drugs

Volumn 19, Issue 1, 2008, Pages 85-90

  Harada, Koji ^a   Sato, Mitsunobu ^a   Ueyama, Yoshiya ^b   Nagayama, Masaru ^a   Hamakawa, Hiroyuki ^c   Nagahata, Shunichirou ^d   Yoshimura, Yasuro ^e   Osaki, Tokio ^f   Ryoke, Kazuo ^g  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d KAGAWA UNIVERSITY   (Japan)

^e SHIMANE UNIVERSITY   (Japan)

^f KOCHI UNIVERSITY   (Japan)

^g TOTTORI UNIVERSITY   (Japan)

Author keywords

Chemotherapy; Oral squamous cell carcinoma; Phase II study; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; ANTINEOPLASTIC AGENT;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER PATIENT; CHEEK MUCOSA; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; GINGIVA; GINGIVA TUMOR; HUMAN; JAW TUMOR; LEUKOPENIA; LIP; MALE; MOUTH; MOUTH CARCINOMA; MOUTH TUMOR; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PALATE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SKIN PIGMENTATION; SQUAMOUS CELL CARCINOMA; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TONGUE; TONGUE TUMOR; TREATMENT RESPONSE; TUMOR LOCALIZATION; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; OXONIC ACID; SURVIVAL ANALYSIS; TEGAFUR;

EID: 36549016715     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3282f0ce4d     Document Type: Article

References (25)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108.
2. Inagi K, Takahashi H, Okamoto M, Nakayama M, Makoshi T, Nagai H. Treatment effects in patients with squamous cell carcinoma of the oral cavity. Acta Otolaryngol 2002; 547 (Suppl):25-29.
3. Shingaki S, Takada M, Sasai K, Bibi R, Kobayashi T, Nomura T, et al. Impact of lymph node metastasis on the pattern of failure and survival in oral carcinomas. Am J Surg 2003; 185:278-284.
4. Schoffski P. The modulated oral fluoropyrimidine prodrug S-1 and its use in gastrointestinal cancer and other solid tumors. Anticancer Drugs 2004; 15:85-106.
5. Shirasaka T, Shimamoto Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, et al. Development of a novel form of 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor-selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996; 7:548-557.
6. Tatsumi K, Fukushima M, Shirasaka T, Fujii S. Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extract. Jpn J Cancer Res 1987; 78:748-755.
7. Shirasaka T, Shimamoto Y, Fukushima M. Inhibition of oxonic acid on gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 1993; 53:4004-4009.
8. Inuyama Y, Kida A, Tsukuda M, Kohno N, Satake B. Late phase II study of S-1 in patients with advanced head and neck cancer. Gan To Kagaku Ryoho 2001; 28:1381-1390.
9. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 mol/l tegafur-0.4 mol/l gimestat-1 mol/l otastat potassium) in advanced gastric cancer patients. Eur J Cancer 2001; 34:1715-1720.
10. Koizumi W, Kurihara M, Nakano S, Hasegawa K. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. S-1 cooperative gastric cancer study group. Oncology 2000; 58:191-197.
11. Ohtsu A, Baba H, Sakata Y, Mitachi Y, Horikoshi N, Sugimachi K, et al. Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 cooperative colorectal carcinoma study group. Br J Cancer 2000; 83:141-145.
12. Saeki T, Takashima S, Sano M, Horikoshi N, Miura S, Shimizu S, et al. A phase II study of S-1 in patients with metastatic breast cancer: a Japanese trial by the S-1 cooperative study group, breast cancer working group. Breast Cancer 2004; 11:194-202.
13. Kawahara M, Furuse K, Segawa Y, Yoshimori K, Matsui K, Kudoh S, et al. Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Br J Cancer 2001; 85:939-943.
14. Inuyama Y, Kida A, Tsukuda M, Kohno N, Satake B. Early phase II study of S-1 in patients with advanced head and neck cancer. Gan To Kagaku Ryoho 1998; 25:1151-1158.
15. Chollet P, Schoffski P, Weigang-Kohler K, Schellens JH, Cure H, Pavlidis N, et al., EORTC Early Clinical Studies Group. Phase II trial with S-1 in chemotherapy-naive patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG). Eur J Cancer 2003; 39:1264-1670.
16. Van den Brande J, Schoffski P, Schellens JH, Roth AD, Duffaud F, Weigang-Kohler K, et al. EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer. Br J Cancer 2003; 88:648-653.
17. Tsukuda M, Kida A, Fujii M, Kono N, Yoshihara T, Hasegawa Y, et al., Chemotherapy Study Group of Head and Neck Cancer. Randomized scheduling feasibility study of S-1 for adjuvant chemotherapy in advanced head and neck cancer. Br J Cancer 2005; 93:884-889.
18. Taguchi T, Inuyama Y, Kanamaru R, Hasegawa K, Akazawa S, Niitani H, et al. Phase I study of S-1. S-1 study group. Gan To Kagaku Ryoho 1997; 24:2253-2264.
19. Hirata K, Horikoshi N, Aiba K, Okazaki M, Denno R, Sasaki K, et al. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clin Cancer Res 1999; 5:2000-2005.
20. Sugimachi K, Maehara Y, Horikoshi N, Shimada Y, Sakata Y, Mitachi Y, et al. An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. Oncology 1999; 57:202-210.
21. Japan Society for Cancer Therapy. Criteria for the evaluation of the clinical effects of solid cancer chemotherapy. J Jpn Soc Cancer Ther 1993; 28:101-130.
22. Harada K, Kawashima Y, Uchida D, Yoshida H. A case of advanced oral squamous cell carcinoma responding to concurrent radiotherapy with S-1. Gan To Kagaku Ryoho 2007; 34:745-747.
23. Ohtsu A, Boku N, Nagashima F, Koizumi W, Tanabe S, Saigenji K, et al. A phase I/II study of S-1 plus cisplatin (CDDP) in patients (pts) with advanced gastric cancer (AGC). Proc Am Soc Clin Oncol 2001; 20:656.
24. Yoshida K, Ninomiya M, Takakura N, Hirabayashi N, Takiyama W, Sato Y, et al. Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin cancer Res 2006; 12:3402-3407.
25. Nakazawa M, Ohnishi T, Ohmae M, Chisoku H, Yui S, Iwai S, et al. Phase II study of a novel oral formation of 5-fluorouracil in combination with low-dose cisplatin as preoperative chemotherapy of oral squamous cell carcinoma. Int J Clin Pharmacol Res 2005; 25:115-122.